Absci to Report Business Updates and Second Quarter 2025 Financial and Operating Results on August 12, 2025

Company Overview - Absci Corporation is a clinical-stage biopharmaceutical company focused on advancing drug discovery through generative design, aiming to create better biologics for patients more rapidly [3] - The company utilizes its Integrated Drug Creation™ platform, which combines AI models with a synthetic biology data engine, to innovate therapeutics targeting challenging therapeutic areas [3] Upcoming Financial Results - Absci will report its business updates and financial results for the second quarter of 2025 after market close on August 12, 2025 [1] - A conference call will be held at 4:30 p.m. Eastern Time to discuss these results and the company's outlook, with a live webcast available on its investor relations website [2] Product Pipeline - Absci is developing a pipeline of AI-designed therapeutics, including ABS-101, aimed at treating inflammatory bowel disease (IBD), and ABS-201, which targets hair regrowth for androgenetic alopecia [3] - The company collaborates with leading pharmaceutical, biotech, tech, and academic institutions to enhance its therapeutic innovations [3]